Pharmaceutical giants Pfizer and Amgen are among 22 strategic companies increasing their operational footprint in Hong Kong. The move signals continued confidence in the region as a hub for global biotech and healthcare operations.
- Pfizer and Amgen are part of a 22-firm expansion effort in Hong Kong
- Both companies hold valuations over HK$1 trillion ($153 billion)
- Expansion aims to utilize Hong Kong as a strategic regional hub
- Move signals confidence in the local biotech and healthcare environment
- Long-term growth strategy focused on the Asia-Pacific market
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.